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risk for hepatocellular carcinoma (HCC). The effect of medium-
term nucleos(t)ide analogue therapy on HCC incidence is unclear;
therefore, we systematically reviewed all the data on HCC inci-
dence from studies in chronic hepatitis B patients treated with
nucleos(t)ide analogues.
Methods:Weperformeda literature search to identify studieswith
chronic hepatitis B patients treated with nucleos(t)ide analogues
forP24 months.
Results: Twenty-one studies including 3881 treated and 534
untreated patients met our inclusion criteria. HCC was diagnosed
in 2.8% and 6.4% of treated and untreated patients, respectively,
during a 46 (32–108) month period (p = 0.003), in 10.8% and 0.5%
of nucleos(t)ide naive patients with and without cirrhosis
(p <0.001) and in 17.6% and 0% of lamivudine resistance patients
with and without cirrhosis (p <0.001). HCC developed less fre-
quently in nucleos(t)ide naive patients compared to thosewithout
virological remission (2.3% vs 7.5%, p <0.001), but therewas no dif-
ference between lamivudine resistance patients with or without
virological response to rescue therapy (5.9% vs 8.8%, p = 0.466).
Conclusions: Chronic hepatitis B patients receivingmedium-term
nucleos(t)ide analogue therapy had a signiﬁcantly lower incidence
of HCC compared to untreated patients but treatment does not
completely eliminate the risk of HCC. Among the treated patients,
cirrhosis, HBeAg negative at baseline and failure to remain in viro-
logical remission were associated with an increased risk of HCC.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide [1]. Its incidence is high in Eastern Asia and
sub-Saharan Africa [1,2], and increasing in several Western low
incidence areas [3]. HCC usually develops in patients with
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erferon-alpha.for developing HCC varies according to the etiology of liver dis-
ease with chronic hepatitis B virus (HBV) infection being globally
the most frequent underlying cause [1,2].
The prognosis of HCC is extremely poor, because therapeutic
interventions are generally ineffective in advanced stages [4].
Screening programs have been applied to detect HCC in early
stages. However, screening programs with determinations of
serum alpha-fetoprotein levels and ultrasonography every 6–
12 months are rather unsatisfactory, with HCC detected in early
stages in less than 50% of cases [5]. Thus, development of preven-
tion strategies is imperative.
The efﬁcacy of primary prevention programs based on the
universal HBV vaccination of all newborns has already become
apparent in many high endemic Asian countries, where HCC inci-
dence among children have declined by 70% [6]. However,
approximately 400 million people who are chronically infected
with HBV will not beneﬁt from immunisation and remain at
increased risk for HCC [7]. Given that the HCC risk is particularly
high in the presence of cirrhosis and/or persistent high viral rep-
lication [1,2,8], antiviral therapy could be a rational approach to
prevent this complication in such patients.
The current therapeutic options for patients with chronic
HBV infection may be summarized into treatment with stan-
dard or pegylated interferon-alpha (IFNa), a drug with antiviral,
immunomodulatory and perhaps antitumoral activities, and
treatment with oral nucleos(t)ide analogues [9–11]. The effect
of IFNa on HCC incidence in patients with chronic hepatitis B
has been evaluated in several studies and meta-analyses. Most
of the data suggest that IFNa treatment may decrease overall
HCC incidence with a more marked effect in sustained respond-
ers. The effect is more evident in Asian than in European stud-
ies possibly related to the lower incidence of HCC in European
patients [12–17]. The effect of oral antiviral therapy on HCC inci-
dence, however, has not been clariﬁed. Therefore, we systemati-
cally reviewed all the data on HCC incidence from studies in
patients with chronic hepatitis B with or without cirrhosis who
were treated with medium-term nucleos(t)ide analogues.
Search strategy and selection criteria
Medline/Pubmed from January 1998 to April 2009 was searched
to identify all medical literature included under the search text10 vol. 53 j 348–356
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terms: ‘‘hepatitis B” and ‘‘cancer”, ‘‘carcinoma” and ‘‘therapy”,
‘‘treatment”, ‘‘lamivudine”, ‘‘adefovir”, ‘‘entecavir”; ‘‘telbivudine”,
‘‘tenofovir”. In addition, a manual search of all relevant review
articles and of the retrieved original studies was performed.
All studies published in English as full papers were included, if
they fulﬁlled all of the following criteria: (1) were randomised
trials or observational cohort studies, (2) had adult patients with
chronic hepatitis B and/or cirrhosis (compensated or decompen-
sated), (3) the patients were treated with nucleos(t)ide analogues
for a mean/median duration of at least 24 months, and (4) data
on the incidence of HCC was available. Studies including patients
with HBV and hepatitis D or C and/or human immunodeﬁciency
virus co-infections were excluded.
The literature search was performed by two independent
reviewers (G.V.P., P.L.), who determined which studies could be
potentially included. Two lists of selected papers were compared
for concordance and discrepancies, were discussed, and, if neces-
sary, arbitrated by a third reviewer (A.L.). Each study in the list of
selected papers was evaluated by two independent reviewers
(G.V.P., S.M.) in order to determine whether it fulﬁlled all the
inclusion criteria. The same two independent reviewers (G.V.P.,
S.M.) extracted data from the selected papers according to a pre-
deﬁned form. Two data summary tables were compared for con-
cordance and a minor discrepancy was identiﬁed in only one
study.Studies and patient characteristics
There were 672 studies initially identiﬁed from the literature
search. Of these, 422 were excluded because they did not include
chronic hepatitis B patients treated with nucleos(t)ide analogues,
198 had a mean/median follow-up of <24 months and 31 did not
report HCC data. Therefore, only 21 studies were included in the
ﬁnal list [18–38]. Studies were considered to be of high quality
for this review if they fulﬁlled three of the following ﬁve criteria:
(a) provided deﬁnitions for HCC diagnosis, (b) described HCC
screening at baseline, (c) described HCC surveillance during ther-
apy, (d) provided HCC data separately in patients with and with-
out cirrhosis, and (e) provided HCC data in relation to virological
response. According to these criteria, 14 studies were character-
ized to be of high [19–22,24–27,29,32,35–38] and 7 to be of
low quality [18,23,28,30,31,33,34]. Ten studies were considered
as large [18,20,22,26,29,32,33,36–38] and 11 as small
[19,21,23–25,27,28,30,31,34,35] if the total number of patients
was more than 100 or less than 100, respectively.
In total, there were 3881 chronic hepatitis B patients with or
without cirrhosis who were treated with nucleos(t)ide analogues
(from 20 to 998 patients in each study). Of these, 1280 (33%)
had cirrhosis, 888 (69%) had compensated and 162 (13%) decom-
pensated cirrhosis, while the severity of cirrhosis was not
reported in 230 (18%) patients. Roughly half (49.2%) of the
patients were hepatitis B e antigen (HBeAg) positive (1909/
3881) (Table 1).
The mean or median age of the patients was between 30 and
40 years in three studies [18,23,32], between 40 and 50 years in
10 studies [21,22,24,25,29,31,34,36–38] and in the non-cirrhotic
patients of one additional study [20], and P50 years in 7 studies
[19,26–28,30,33,35] and in the cirrhotic patients of one study
[20]. Most patients were males (79.7%) and the majority was Cau-
casians (50.6%) or Asians (48.0%). HCC screening at baseline wasJournal of Hepatology 201reported to be performed in 15 studies including 2807 patients
[18,19,21,22,24–27,29,32,34–38] and HCC surveillance during
therapy (mostly by alpha-fetoprotein and/or abdominal ultra-
sound) at least every 6 months in 11 of these studies including
1553 patients [19,21,22,25–27,32,35–38], while HCC screening
and/or surveillance were not described or performed in the
remaining studies (Table 2). It should be noted that the propor-
tion of cirrhotic patients was signiﬁcantly higher in studies with
than without reported strategies for HCC surveillance (650/1553
or 41.9% vs 630/2328 or 27.1%, p < 0.001).
Sixteen studies included nucleos(t)ide naive chronic hepatitis
B patients with lamivudine monotherapy used initially in 14 [18–
22,24–28,32,34–36], emtricitabine in one [23] and adefovir in the
remaining study [29]. Five studies included patients with lamivu-
dine resistance treated with adefovir monotherapy or adefovir
and lamivudine combination therapy [30,31,33,37,38]. The mean
or median duration of follow-up was 24–36 months in 10 studies
[20–23,26,28,30,31,37,38] and >36 months in 11 studies
[18,19,24,25,27,29,32–36] (Table 3).
Three of the 21 studies included not only treated but also
untreated chronic hepatitis B patients followed for at least
24 months. Of note, 215 untreated controls were included in
the only randomised controlled trial [22], 195 historical
untreated controls were included in a cohort study [26] and
124 untreated patients were included in a single center study
[32]. The untreated patients in the second study were younger,
had lower baseline ALT levels and longer follow-up compared
to the treated patients, while the untreated patients in the third
study had similar characteristics as the treated patients in that
study (Tables 1–3).Incidence of HCC and timing of HCC diagnosis
In total, 168 (4.3%) chronic hepatitis B patients receiving nucle-
os(t)ide analogue therapy were diagnosed to have HCC during a
mean/median follow-up of 40 (24–102) months (Table 4). In 10
studies including nucleos(t)ide naive patients that provided data
on the timing of HCC diagnosis, HCC was diagnosed within the
ﬁrst year of treatment in 25 (22.7%) patients and after the ﬁrst
year in 85 (77.3%) of 110 cases [19,20,22,23,25–29,35,36]. In 5
studies including patients with lamivudine resistance, 13
patients had HCC at the onset of adefovir and/or lamivudine
therapy, 9 were diagnosed within the ﬁrst year, and 18 after
the ﬁrst year of rescue therapy for lamivudine resistance
[30,31,33,37,38].Risk factors for HCC
Patients naive to nucleos(t)ide analogues
In the 16 studies including nucleos(t)ide naive patients, HCC was
diagnosed in 126 (3.8%) of 3287 cases during a mean/median fol-
low-up of 42 (24–102) months [18–29,32,34–36]. In the three
studies with untreated controls [22,26,32], which were all of high
quality and large, HCC was detected signiﬁcantly less frequently
in treated (22/779 or 2.8%) than in untreated patients (34/534 or
6.4%, p = 0.003). The incidence of HCC was signiﬁcantly higher in
untreated patients (34/534 or 6.4%) compared to both treated
patients remaining in virological remission (9/353 or 2.5%,0 vol. 53 j 348–356 349
Table 1. Baseline characteristics of chronic hepatitis B (CHB) patients who were treated or not treated with nucleos(t)ide analogues.
Reference Study design Primary study question Patients
n
Severity of CHB
n
HBeAg pos./neg.
Lok, 2003 [18] MC, RE, data from
clinical trials
Safety of long-term LAM 998 CHB: 944
Compensated Cirr: 54
998/0
Andreone, 2004 [19] SC, PR cohort study HCC risk in cirrhotic patients
under LAM
22 Compensated Cirr: 22
(Child A/B: 16/6)
0/22
Di Marco, 2004 [20] MC, RE cohort study Clinical outcome of chronic
HBV patients under LAM 656
656 CHB: 353 0/656
Compensated Cirr*: 198
Decompensated Cirr*: 105
Gaia, 2004 [21] SC, RE cohort study Clinical and virological
impact of long-term LAM
94 CHB: 72
Compensated Cirr: 22
0/94
Liaw, 2004 [22] PR, RA controlled trial Efﬁcacy of LAM in advanced
CHB
Treated: 436 CHB (Ishak’s stage 4): 176 252/184
Compensated Cirr: 260
(Child A/B: 416/20)
Untreated: 215 CHB (Ishak’s stage 4): 76 124/91
Compensated Cirr: 139
(Child A/B: 197/18)
Gish, 2005 [23] Phase II trial Safety & efﬁcacy of
emtricitabine
98 CHB: 98 77/21
Moskovitz, 2005 [24] SC, RE cohort study Response to long-term LAM 71 CHB: 40 38/33
Compensated Cirr: 31
Acuta, 2005 [25] SC, PR cohort study Long-term efﬁcacy of LAM 20 CHB: 20 9/11
Papatheodoridis, 2005 [26] MC, RE cohort study Outcome under long-term
LAM
Treated: 201 CHB: 137 0/201
Compensated Cirr: 64
Untreated: 195 CHB: 127 0/195
Compensated Cirr: 68
Di Marco, 2005 [27] SC, RE cohort study HBV DNA suppression &
course under LAM
59 Cirr: 59
(Child A/B/C: 45/9/5)
12/47
Manolakopoulos, 2006 [28] MC, RE cohort study Prediction of response to
long-term LAM
79 CHB: 52 0/79
Compensated Cirr: 27
Hadziyannis, 2006 [29] MC, PR cohort study Long-term efﬁcacy of ADV in
HBeAg-negative CHB
125 CHB: 95 0/125
Compensated Cirr: 30
Rapti, 2007 [30] SC, RA controlled trial Efﬁcacy of ADV LAM-
resistance CHB
42 CHB: 26
Compensated Cirr: 16
0/42
Buti, 2007 [31] SC, RE cohort study Response to ADV in LAM-
resistance patients
54 CHB: 34
Compensated Cirr: 20
29/25
Yuen, 2007 [32] SC, PR cohort study Efﬁcacy of long-term LAM in
HBeAg-positive CHB
Treated: 142 CHB: 142 142/0
Untreated: 124 CHB: 124 124/0
Lampertico, 2007 [33] SC, PR cohort study Efﬁcacy of LAM + ADV in
LAM-resistance CHB
145 CHB: 39 21/124
Cirr: 106
Wong, 2008 [34] SC, PR/RE cohort study Efﬁcacy of long-term LAM in
HBeAg-positive CHB with
severe exacerbation
60 CHB: 17
Compensated Cirr: 43
60/0
Kilic, 2008 [35] SC, PR cohort study Efﬁcacy of long-term LAM in
HBeAg-negative
decompensated cirr
68 Cirr:
68 (Child A/B/C: 35/22/11)
0/68
Nishida, 2008 [36] MC, PR cohort study Efﬁcacy of long-term LAM in
CHB with or without cirr
158 CHB: 87
Compensated Cirr: 28
Decompensated Cirr: 43
96/60
Akuta, 2008 [37] SC, RE cohort study Efﬁcacy of and HCC
incidence during ADV + LAM
in LAM-resistance CHB
183 CHB: 127 109/74
Cirr: 56
Idilman, 2009 [38] SC, RE cohort study Efﬁcacy of 6 months
ADV + LAM followed by ADV
alone in LAM-resistance CHB
170 CHB: 142 68/102
Compensated Cirr: 28
MC: multicenter, SC: single center, PR: prospective, RE: retrospective, RA: randomised, Cirr: cirrhosis, LAM: lamivudine, ADV: adefovir.
* Compensated and decompensated Ci: Child A and B/C, respectively.
 Histological cirrhosis or bridging ﬁbrosis.
 Twenty-nine patients with severe acute exacerbation of CHB (CHB: 16, Ci: 13).
Reviewp = 0.015) as well as treated patients with virological break-
throughs or no response (12/426 or 2.8%, p = 0.016) (Tables 4
and 5).
Among the treated patients, HCC developed signiﬁcantly more
frequently in patients with cirrhosis (114/1054 or 10.8%) com-
pared to chronic hepatitis B patients without cirrhosis (12/2233
or 0.5%) (p <0.001) (Fig. 1). The higher HCC rate in patients with
cirrhosis vs those without cirrhosis was also observed in studies
with high (108/928 or 11.6% vs 11/1122 or 1.0%, p <0.001) [19–350 Journal of Hepatology 20122,24–27,29,32,35,36] and low quality (6/124 or 4.8% vs 1/1111
or 0.1%, p <0.001) [18,23,28,34] as well as in large (70/782 or
9.0% vs 10/1934 or 0.5%, p <0.001) [18,20,22,26,29,32,33,36–38]
and small studies (44/272 or 16.2% vs 2/299 or 0.7%, p <0.001)
[19,21,23–25,27,28,30,31,34,35]. In 12 studies providing data on
the HCC incidence in relation to the severity of cirrhosis [18–
22,24,26–29,34,36], HCC was diagnosed in 78 (10.0%) of 779
patients with compensated and 18 (12.2%) of 148 patients with
decompensated cirrhosis (p = 0.522) (Table 5).0 vol. 53 j 348–356
Table 2. Baseline characteristics of chronic hepatitis B (CHB) patients who were treated or not treated with nucleos(t)ide analogues.
Reference Patients
n
Age*
years
Sex
M/F
Race
C/A
ALT*
IU/L
Serum
HBV DNA
HCC screening
At baseline On therapy
Lok, 2003 [18] 998 32 760/238 243/714 1.6  ULN 79 pg/ml aFP + U/S Unknown
Andreone, 2004 [19] 22 53 18/4 22/0 192 16 pg/ml aFP + U/S aFP + U/S
Di Marco, 2004 [20] CHB: 353 47 279/74 353/0 2–5  ULN NA Unknown Unknown
Ci: 303 52 268/35 303/0 2–5  ULN NA
Gaia, 2004 [21] 94 46 75/19 94/0 3  ULN 1–10 pg/ml U/S U/S
Liaw, 2004 [22] Treated: 436 43 370/66 0/426 70 11.7 mEq/ml aFP + U/S aFP + U/S
Untreated: 215 44 182/33 0/215 68 21.5 mEq/ml
Gish, 2005 [23] 98 36 69/29 9/86 66 7.6 log10 cp/ml Unknown Unknown
Moskovitz, 2005 [24] 71 47 53/18 33/38 NA NA U/S Unknown
Acuta, 2005 [25] 20 44 16/4 0/20 100 32  106 gEq/ml U/S U/S
Papatheodoridis, 2005 [26] Treated: 201 52 167/34 201/0 98 2  106 cp/ml aFP + U/S aFP + U/S
Untreated: 195 49 160/35 195/0 68 4.5 pg/ml (in cirrhotics)
Di Marco, 2005 [27] HBeAg+: 12 54 10/2 12/0 163 1.3  107 gen./ml aFP + U/S aFP + U/S
HBeAg: 47 52 42/5 47/0 216 1.4  107 gen./ml
Manolakopoulos, 2006 [28] 79 50 64/15 79/0 110 6 log10 cp/ml Unknown Unknown
Hadziyannis, 2006 [29] 125 47 103/22 87/34 100 7 log10 cp/ml aFP + U/S Unknown
Rapti, 2007 [30] 42 56 39/3 42/0 123 8  106 cp/ml Unknown Unknown
Buti, 2007 [31] 54 51 44/10 54/0 113 7 log10 cp/ml Unknown Unknown
Yuen, 2007 [32] Treated: 142 34 106/36 0/142 65 8.7 log10 cp/ml aFP aFP
Untreated: 124 33 90/34 0/124 49 6.8 log10 cp/ml
Lampertico, 2007 [33] 145 56 122/23 145/0 58 6 log10 cp/ml Unknown Unknown
Wong, 2008 [34] (a) 29 39 25/14 0/29 1135 8 log10 cp/ml U/S Unknown
(b) 31 44 31/0 0/31 76 7.3 log10 cp/ml
Kilic, 2008 [35] 68 52 51/17 68/0 104 4  103 IU/ml aFP + U/S aFP + U/S
Nishida, 2008 [36] 158 49 101/57 0/158 105 6.8 log10 cp/ml aFP + DCP + U/S aFP + DCP + U/S
Akuta, 2008 [37] 183 47 150/33 0/183 130 7.3 log10 cp/ml U/S U/S
Idilman, 2009 [38] 170 43 130/40 170/0 100 7 log10 cp/ml aFP + U/S aFP + U/S
M/F: males/females, C: Caucasians, A: Asians, HCC: hepatocellular carcinoma, Ci: cirrhosis, NA: not available, aFP: alpha-fetoprotein, DCP: des-c-carboxy-prothrombin,
U/S: ultrasound.
* Mean or median values.
 U/S at baseline in patients with albumin <3.5 g/dl and during follow-up in patients with aFP elevations.
 (a) Patients with severe acute exacerbation of CHB, (b) CHB patients without severe acute exacerbation.
JOURNAL OF HEPATOLOGYIn 10 studies providing data on the HCC incidence in relation
to virological response, HCC was diagnosed in 64 (7.5%) of 852
patients with virological non-response or breakthrough but also
in 23 (2.3%) of 982 patients in virological remission (p <0.001)
[19–22,25–29,32] (Table 5, Fig. 1). The HCC rate was signiﬁcantly
lower in patients remaining in virological remission vs those not
in remission in studies with high quality (23/943 or 2.4% vs 63/
1115 or 5.7%, p <0.001) [19–22,25–27,29,32], while only one of
the studies with low quality provided such data [28]. Similarly,
the HCC rate was signiﬁcantly lower in patients remaining in
virological remission in both large (20/856 or 2.3% vs 39/704 or
5.5%, p = 0.002) [20,22,26,29,32] and small studies (3/126 or
2.4% vs 25/148 or 16.9%, p <0.001) [19,21,25,27,28]. The sensitiv-
ity of the HBV DNA assay used in each study did not affect the
association between virological response and HCC development.
HCC was diagnosed more frequently in patients with virological
non-response or breakthrough than in those in virological remis-
sion from studies using sensitive HBV DNA assays (lower limit of
detection 61000 cp/ml) (43/594 or 7.2% vs 13/564 or 2.3%,
p <0.001) [19,21,22,26–29,32] as well as studies using insensitive
HBV DNA assays (lower limit of detection P100,000 cp/ml) (21/
258 or 8.1% vs 10/418 or 2.4%, p = 0.001) [20,25]. In two studies
with only cirrhotic patients followed for a median of 42–
44 months, HCC was also detected signiﬁcantly less frequently
in cirrhotics compared to those without virological remission
(3/36 or 8.3% vs 17/45 vs 37.8%, p = 0.004) [19,27].
HCC was reported to develop at a higher rate in studies
with regular HCC surveillance compared to those without
(6.6% vs 2.3%, p <0.001); in studies including patients with aJournal of Hepatology 201mean/median age P50 compared to those including <50 years
(6.0% vs 2.8%, p <0.001); and in studies with almost exclusively
(>85%) HBeAg-negative patients compared to studies with
mostly HBeAg-positive patients (5.5% vs 0.5%, p <0.001)
(Table 5). The incidence of HCC did not differ signiﬁcantly
between studies including almost exclusively (>85%) Caucasian
or Asian patients (6.1% vs 4.9%, p = 0.283) (Table 5). The effect
of gender could not be determined, as males represented the
majority of patients in all studies.
Patients with lamivudine resistance
In ﬁve studies including patients with lamivudine resistance
treated with adefovir with or without continued lamivudine for
a mean/median period of 30 (24–42) months [30,31,33,37,38],
HCC was diagnosed in 42 (7.1%) of 594 cases (Tables 4 and 5).
Since only two of the ﬁve studies were classiﬁed to be of high
quality and both studies did not provide HCC data in relation to
the presence of cirrhosis or virological response, subgroup analy-
ses according to the quality of the studies were not performed for
patients with lamivudine resistance.
In the four studies which provided data on the HCC incidence
in patients with lamivudine resistance in relation to the presence
of cirrhosis [30,31,33,38], HCC was reported to develop exclu-
sively in cirrhotic patients (30/170 or 17.6% vs 0/241 or 0%,
p < 0.001) (Fig. 1). In the four studies providing data on the HCC
incidence in relation to virological response to rescue therapy
[30,31,33,37], HCC was detected in 21 (20.2%) of 104 patients
with viremia and in 19 (5.9%) of 320 patients in virological0 vol. 53 j 348–356 351
Table 3. Treatment characteristics in chronic hepatitis B (CHB) patients receiving nucleos(t)ide (NUC) analogue therapy.
Reference Type of
patients
Initial therapy Maintained
virological
response (VR)*,
n
No VR or
breakthroughs
n
Rescue therapy**,
Type: n
Duration of
study
follow-up,
months
VR during
rescue
therapy,
n
Type Duration months
Lok, 2003 [18] NUC naive LAM 48 (0–77) NA NA None 48 (0–77) –
Andreone, 2004 [19] NUC naive LAM 42 (12–74) 9 13 None 42 (12–74) –
Di Marco, 2004 [20] NUC naive LAM 24 (1–66) 407 249 None 24 (1–66) –
Gaia, 2004 [21] NUC naive LAM 33 (12–54) 40 54 None 33 (12–54) –
Liaw 2004 [22] NUC naive
Untreated
LAM 32 (0–42) 227 209 None 32 (0–42)
32 (0–42)
–
Gish, 2005 [23] NUC naive Emtricitabine 24 41 36 None 24 –
Moskovitz, 2005 [24] NUC naive LAM 40 (12–60) 19 52 None 40 (12–60) –
Acuta, 2005 [25] NUC naive LAM 102 (80–104) 11 9 Other + LAM: 3 IFN: 2 102 (80–104) 3
Papatheodoridis, 2005 [26] NUC naive
Untreated
LAM 46 (12–95) 92 109 ADV: 26, ADV + LAM: 53 46 (12–95)
73 (12–162)
66
Di Marco, 2005 [27] NUC naive LAM 44 (11–78) 27 32 None 44 (11–78) –
Manolakopoulos, 2006 [28] NUC naive LAM 31 (6–56) 39 40 ADV ± LAM: 20 31 (6–56) NA
Hadziyannis, 2006 [29] NUC naive ADV 45–57 96 29 LAM ± ADV: 11 45–57 NA
Rapti, 2007 [30] LAM resistance LAM 32 (12–84) 0 42 ADV: 14, ADV + LAM: 28 38 (9–53) 12 months:
30/42
Buti, 2007 [31] LAM resistance LAM 33 ± 23 0 54 ADV: 28, ADV + LAM: 26 30 ± 16 38
Yuen, 2007 [32] NUC naive
Untreated
LAM 90 (27–128) 34 108 None 90 (27–128)
108 (31–127)
–
Lampertico, 2007 [33] LAM resistance LAM NA 0 145 ADV + LAM: 145 42 (12–74) 108
Wong, 2008 [34] NUC naive LAM (a) 42 (12–85)
(b) 46 (12–101)
21
NA
8
NA
ADV: 7
NA
42 (12–85)
95 (42–101)
5
Kilic, 2008 [35] NUC naive LAM 45 ± 18 48 20 ADV + LAM: 20 50 ± 19 NA
Nishida, 2008 [36] NUC naive LAM 40 ± 13 NA Breakthroughs:
78
ADV + LAM: NA 40 ± 13 NA
Akuta, 2008 [37] LAM resistance LAM 35 (7–130) 0 183 ADV + LAM: 183 26 (6–54) 144
Idilman, 2009 [38] LAM resistance LAM 36 (6–108) 0 170 ADV + LAM
 6 months  ADV: 170
24 12 months:
84/141
LAM: lamivudine, ADV: adefovir, IFN: interferon-alfa, NA: not available.
* Virological response deﬁned as undetectable HBV DNA with lower limit of detection of HBV DNA assays 35–1000 copies/ml in 15 studies [19,21,22,24,26–34,36,37] and a
wide range of sensitivities in other studies (400 or 4700 copies/ml [35], 2000 copies/ml [38], 4700 copies/ml [23], 100,000 copies/ml [20] and P0.7 mEq/ml [18,25]).
** The main therapy in studies with LAM-resistance patients [30,31,33,37,38].
 IFN in 2 and glycyrrhizin in 1 patient.
 (a) Twenty-nine patients with severe acute exacerbation of CHB and (b) 31 CHB patients without severe acute exacerbation.
Reviewremission (p <0.001). This difference in HCC incidence, however,
was not statistically signiﬁcant when the 13 patients with HCC
at the onset of adefovir therapy were excluded (8/91 or 8.8% vs
19/320 or 5.9%, p = 0.466) (Table 5 and Fig. 1). Similar ﬁndings
were observed when only large studies were included in the anal-
yses [33,37,38].
Comparisons between nucleos(t)ide naive patients and patients with
lamivudine resistance
The cumulative HCC rate was signiﬁcantly higher in patients with
lamivudine resistance compared to that in all nucleos(t)ide naive
patients (42/594 or 7.1% vs 126/3287 or 3.8%, p = 0.001) (Table 5).
It should be noted that the proportion of patients with cirrhosis
was lower in studies with nucleos(t)ide naive patients than those
including patients with lamivudine resistance (1054/3287 or
32.1% vs 226/594 or 38.0%, p = 0.005) (Table 1). Among cirrhotics,
HCC developed signiﬁcantly more frequently in patients with
lamivudine resistance than in those who were nucleos(t)ide
naive (30/170 or 17.6% vs 114/1054 or 10.8%, p = 0.015) (Table 5).
The median duration of follow-up was shorter in studies of
patients with lamivudine resistance ranging from 24 to
36 months in four studies and exceeded 36 months in only one
(20.0%) study, while it exceeded 36 months in 10 (62.5%) of 16
studies with nucleos(t)ide naive patients (p = 0.149) (Table 3).
When all 14 studies with nucleos(t)ide naive or lamivudine
resistance patients and data on HCC incidence in relation to viro-352 Journal of Hepatology 201logical response were taken into account [19–22,25–33,37], HCC
was found to develop in 85 (8.9%) of 956 patients with detectable
viremia and in only 42 (3.2%) of 1302 patients in virological
remission (p <0.001). HCC developed more frequently in patients
in virological remission after initiation of rescue therapy for lam-
ivudine resistance (19/320 or 5.9%) than in patients remaining in
virological remission under the initial nucleos(t)ide therapy (23/
982 or 2.3%, p = 0.003).Discussion
The results of our systematic review show that the medium-term
risk of HCC is signiﬁcantly lower in chronic hepatitis B patients
receiving effective oral antiviral therapy. In three studies includ-
ing untreated controls, HCC developed in 2.8% of treated and in
6.4% of untreated chronic hepatitis B patients (p = 0.003).
Although only one of these three studies was randomised [22],
the untreated controls had many similar characteristics with
the treated patients in the second study [26] and were selected
to match the treated patients in the third study [32]. It should
be noted that treatment signiﬁcantly reduced the HCC incidence
in the only randomised trial [22]. Given the beneﬁts of antiviral
therapy, it is unethical not to offer treatment to chronic hepatitis
B patients who meet treatment criteria. These data therefore rep-
resent the best evidence supporting the efﬁcacy of nucleos(t)ide0 vol. 53 j 348–356
Table 4. Development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients who were treated with nucleos(t)ide analogues or remained
untreated.
Reference Patients with HCC,
n/N
Patients with HCC,
n/N
Timing of HCC diagnosis
after treatment onset,
months
Total CHB Cirrhosis Virological remission
All Comp. Decomp. Yes No
Lok, 2003 [18] 0/998 0/944 0/54 0/54 0/0 NA NA –
Andreone, 2004 [19] 11/22 0/0 11/22 11/22 0/0 1/9 10/13 Median: 34 (9–58)
[3 cases within ﬁrst year]
Di Marco, 2004 [20] 31/656 4/353 27/303 21/198* 6/105* 10/407 21/249 [5 cases within ﬁrst year]
Gaia, 2004 [21] 7/94 1/72 6/22 6/22 0/0 NA NA Median: 30 (8–39)
Liaw, 2004 [22] Treated:
Untreated:
17/436
16/215
0/176
NA
17/260
NA
17/260
NA
0/0
0/0
8/227
–
9/209
–
[3 cases within ﬁrst year]
[2 cases within ﬁrst year]
Gish, 2005 [23] 1/98 1/98 0/0 0/0 0/0 NA NA [1 case within ﬁrst year]
Moskovitz, 2005 [24] 3/71 0/40 3/31 3/31 0/0 NA NA NA
Acuta, 2005 [25] 0/20 0/20 0/0 0/0 0/0 0/11 0/9 –
Papatheodoridis, 2005 [26] Treated:
Untreated:
4/201
15/195
0/137
1/127
4/64
14/68
4/64
14/68
0/0
0/0
1/92
–
3/109
–
10, 33, 54, 60
48 (8–157)
Di Marco, 2005 [27] 9/59 0/0 9/59 NA NA 2/27 7/32 Median: 13 (6–28)
[4 cases within ﬁrst year]
Manolakopoulos, 2006 [28] 1/79 0/52 1/27 1/27 0/0 0/39 1/40 14
Hadziyannis, 2006 [29] 6/125 1/95 5/30 5/30 0/0 1/96 5/29 112–219
[1 case at 12 months]
Rapti, 2007 [30] 3/42 3/26 3/16 3/16 0/0 2/30 1/12 13–35
Buti, 2007 [31] 2/54 0/34 2/20 2/20 0/0 1/38 1/16 [1 case within ﬁrst year]
Yuen, 2007 [32] Treated:
Untreated:
1/142
3/124
1/142
3/124
0/0
0/0
0/0
0/0
0/0
0/0
0/34
–
1/108
–
NA
NA
Lampertico, 2007 [33] 23/145 0/39 23/106 NA NA 6/108 17/37 Median: 12 (3–38)
[6 cases within ﬁrst year]
Wong, 2008 [34] 5/60 0/17 5/43 5/43 0/0 NA NA NA
Kilic, 2008 [35] 9/68 0/0 9/68 NA NA NA NA 6–84 [1 case within ﬁrst year]
Nishida, 2008 [36] 21/158 4/87 17/71 5/28 12/43 NA NA [6 cases within ﬁrst year]
Akuta, 2008 [37] 12/183 NA NA NA NA 10/144 2/39 Median: 14 (1–54)
[3 cases within ﬁrst year]
Idilman, 2009 [38] 2/170 0/142 2/28 2/28 0/0 NA NA 0, 12
Comp: compensated, Decomp: decompensated, NA: not available, n/N: n the number of cases with HCC in each group and N total number of cases (with and without HCC)
in each group.
* Compensated and decompensated cirrhosis: Child A and B/C, respectively.
 Twelve patients had HCC at the onset of adefovir and lamivudine and were not taken into account in timing of HCC after treatment onset.
JOURNAL OF HEPATOLOGYanalogue therapy in reducing the incidence of HCC in chronic
hepatitis B patients.
Achievement of virological remission after the initial treat-
ment course was found to be extremely important for the reduc-
tion of HCC incidence. In studies including nucleos(t)ide naive
patients, HCC developed signiﬁcantly less frequently in patients
remaining in virological remission than in those with virological
breakthrough or no response (2.3% vs 7.5%, p < 0.001). This
ﬁnding is in agreement with the well known association between
levels of HBV replication and HCC risk [8]. It is not surprising
that viral suppression decreased but did not eliminate the risk
of HCC in chronic HBV patients because HBV DNA may have
already integrated into the host genome before the onset of
treatment and may have already resulted in genomic alterations
and/or chromosomal instability [39,40]. Furthermore, in patients
who have been infected for a long time or who have already
progressed to cirrhosis, malignant transformation of hepatocytes
may be present before the onset of treatment. Finally, some of
the tumours may have been present at the start of treatment
and were not detected by routine clinical evaluations. The
latter hypothesis is in agreement with the ﬁnding that
approximately one fourth (23%) of HCC cases in nucleos(t)ide
naive patients were diagnosed within the ﬁrst year of
treatment.Journal of Hepatology 201The rate of HCC was signiﬁcantly higher in lamivudine resis-
tance than in nucleos(t)ide naive patients (7.1% vs 3.8%,
p = 0.001) despite a shorter duration of follow-up. This is partly
related to the more frequent presence of cirrhosis among patients
with lamivudine resistance, but even among cirrhotics, the inci-
dence of HCC was signiﬁcantly higher in patients with lamivu-
dine resistance than in those who were nucleos(t)ide naive
(18% vs 11%, p = 0.015). Achievement of virological response did
not seem to signiﬁcantly reduce the HCC risk in patients with
lamivudine resistance, as HCC was detected in 9% of such patients
with and in 6% of those without detectable viremia during rescue
therapy (p = 0.466). These data suggest that the maintenance of
viral suppression over a long period of time is needed to reduce
the risk of HCC. It has also been suggested that mutations associ-
ated with lamivudine resistance, in particular, changes at posi-
tion 181 of the reverse transcriptase domain of the HBV
polymerase have direct oncogenic potential [41,42].
It is well known that the HCC risk is highest among untreated
chronic HBV patients with cirrhosis and that severe ﬁbrosis and
cirrhosis predispose to the development of HCC [1,2,4]. Our data
show that the risk of HCC remains high in cirrhotic patients
receiving nucleos(t)ide analogue therapy. HCC developed in 11%
of cirrhotic and in only 0.5% of non-cirrhotic chronic hepatitis B
patients who were naive to nucleos(t)ide agents (p < 0.001) and0 vol. 53 j 348–356 353
Table 5. Incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B patients who were treated or not treated with oral antivirals.
Subgroups of patients Studies, n [References numbers] Mean/Median follow-up (months) No. of patients Patients with HCC p value
Nucleos(t)ide naive patients 16 [18–29,32,34–36] 42 (24–102) 3287 126 (3.8%)1
Treatment effect 0.003
Treated 3 [22,26,32] 46 (32–90) 779 22 (2.8%)
Untreated 3 [22,26,32] 73 (32–108) 534 34 (6.4%)
Presence of cirrhosis <0.001
No cirrhosis 13 [18,20–26,28,29,32,34,36] 40 (24–102) 2233 12 (0.5%)
Cirrhosis 13 [18–22,24,26–29,34–36] 40 (24–52) 1054 114 (10.8%)2
Severity of cirrhosis 0.522
Compensated cirrhosis 12 [18–22,24,26–29,34,36] 40 (24–52)# 779 78 (10.0%)
Decompensated cirrhosis 3 [20,27,36] 24 (12–36)# 148 18 (12.2%)
Virological response 10 [19–22,25–29,32] 39 (24–102) <0.001
Virological remission 982 23 (2.3%)3
No virological remission– 852 64 (7.5%)
HCC surveillance <0.001
No 7 [18,20,23,24,28,29,34] 40 (24–52) 2087 47 (2.3%)
Yes 9 [19,21,22,25–27,32,35,36] 42 (32–102) 1200 79 (6.6%)
Mean/median age <0.001
<50 years 10 [18,21–25,29,32,34,36] 42 (24–102) 2202 61 (2.8%)
P50 years 6 [19,20,26–28,35] 39 (24–45) 1085 65 (6.0%)
HBeAg status (>85% of patients) <0.001
HBeAg positive 3 [18,32,34] 48 (44–90) 1200 6 (0.5%)
HBeAg negative 7 [19–21,26,28,29,35] 39 (24–45) 1245 69 (5.5%)
Race (>85% of patients) 0.283
Caucasians 7 [19–21,26–28,35] 36 (24–45) 1179 72 (6.1%)
Asians 6 [22,23,25,32,34,36] 42 (24–102) 914 45 (4.9%)
Patients with lamivudine resistance 5 [30,31,33,37,38] 30 (24–42) 594 42 (7.1%)4
Presence of cirrhosis 4 [30,31,33,38] 31 (24–42) <0.001
No cirrhosis 241 0
Cirrhosis 170 30 (17.6%)5
Virological response during rescue therapy 4 [30,31,33,37] 31 (26–42) 0.466
Virological remission 320 19 (5.6%)6
No virological remission– 91 8 (8.8%)
1 vs 4, p = 0.001; 2 vs 5, p = 0.015; 3 vs 6, p = 0.003.
# The duration of follow-up was not provided separately for patients with compensated and decompensated cirrhosis in one study [27].
– Virological non-response or breakthrough.
Reviewin 18% of cirrhotic and 0% of non-cirrhotic patients with lamivu-
dine resistance (p < 0.001). The effect of the severity of cirrhosis
(compensated vs decompensated) on HCC risk could not be eval-
uated because of the small number of patients.
Other factors found to be associated with the risk of HCC were
older age, regular HCC surveillance and inclusion of HBeAg nega-
tive cases. Older age is a well known risk factor for HCC [1,2,4],
but the higher HCC rate in the studies with mean/median age
P50 years vs <50 years might be, at least partly, related to the
higher proportion of cirrhotic patients in the studies with older
patients. Indeed, cirrhosis was present in a higher percent of
patients in studies with mean/median age P50 years (543/1085
or 50% vs 511/2202 or 23%, p < 0.001) (Table 1). The association
between HCC risk and HCC surveillance may be related to a
higher proportion of patients with cirrhosis in studies with HCC
surveillance. The proportion of nucleos(t)ide naive patients with
cirrhosis was signiﬁcantly higher in studies which reported regu-
lar HCC surveillance [19,21,22,25–27,32,35,36] than those which
did not [18,20,23,24,28,29,34] (566/1200 or 47% vs 488/2087 or
23%, p <0.001). The association between HCC risk and HBeAg-
negative status may be related to the older age and more
frequent presence of cirrhosis in HBeAg-negative patients. The
proportion of patients with cirrhosis was signiﬁcantly higher in
studies with almost exclusively HBeAg negative [19–
21,26,28,29,35] than studies with predominantly HBeAg-positive
patients [18,32,34] (536/1245 or 43% vs 97/1200 or 8%, p <0.001)
(Table 1).354 Journal of Hepatology 201In conclusion, medium-term nucleos(t)ide analogue therapy
signiﬁcantly reduces but it does not completely eliminate the risk
of HCC, particularly in patients with pre-existing cirrhosis.
Patients with cirrhosis undergoing antiviral treatment should
continue to undergo HCC surveillance. Maintenance of virological
remission is important for the reduction of HCC risk. Our ﬁndings
suggest that HCC risk is increased in patients who experience
virologic breakthrough even if HBV replication is subsequently
suppressed by rescue therapy. This observation provides further
evidence that lamivudine is not an optimal ﬁrst-line treatment
for chronic hepatitis B, as it is associated with very high rates
of drug resistance during long-term treatment. Our study is lim-
ited by the poor quality of many of the included studies, the het-
erogeneous patient populations, the variations in treatment
regimens and patient monitoring, the differences in deﬁnitions
of response, and the wide range in sensitivity of HBV DNA assays
used to assess virological response and the different duration of
follow-up. In addition, because incidence of HCC was not a pri-
mary outcome in these studies, details regarding screening of
HCC at baseline and HCC surveillance during therapy, diagnostic
criteria of HCC and timing of HCC diagnosis were not speciﬁed in
most studies. Nevertheless, the large number of patients and the
results of subgroup analyses reinforce the validity of our conclu-
sions. The vast majority of the current data on HCC risk in chronic
hepatitis B patients treated with nucleos(t)ide analogues come
from studies on lamivudine. It is anticipated that the newer
nucleos(t)ide analogues, such as entecavir and tenofovir, will fur-0 vol. 53 j 348–356
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Fig. 1. Incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B
patients who were treated with nucleos(t)ide analogue(s) (NUC) for a mean/
median of 40 (24–102) months in relation to the presence of cirrhosis,
virological remission, and development of lamivudine (LAM) resistance.
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